Oral formulations of fentanyl products and the benefit of their use in breakthrough cancer pain
MetadataShow full item record
This item's downloads: 203 (view details)
Cited 0 times in Scopus (view citations)
Handsaker, Scott, Dempsey, Laura, & Fabby, Carole. (2015). Use of oral formulations of fentanyl for breakthrough cancer pain. International Journal of Palliative Nursing, 21(4), 168-172. doi: 10.12968/ijpn.2015.21.4.168
Pain is one of the most common symptoms that palliative care teams face on a daily basis, affecting up to 70% of people with a malignancy (Soden et al, 2010) and significantly impacting on a patients quality of life (QoL) (Bornemann-Cimenti et al, 2013). Breakthrough cancer pain (BTCP) is identified as sudden in onset, self-limiting, severe in intensity, and with an average duration of 30 minutes (Handsaker et al, 2013; Bhatnagar, 2014). It is estimated to be prevalent in 40-80% of those with cancer pain (Handsaker et al, 2013).